Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 38.5% in December

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 88,900 shares, a drop of 38.5% from the November 30th total of 144,600 shares. Currently, 2.2% of the shares of the stock are sold short. Based on an average trading volume of 1,760,000 shares, the days-to-cover ratio is presently 0.1 days.

Virax Biolabs Group Price Performance

Shares of NASDAQ VRAX opened at $2.10 on Friday. The firm has a fifty day moving average of $1.95 and a 200 day moving average of $2.06. Virax Biolabs Group has a one year low of $0.60 and a one year high of $9.00.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.